Compare Crispr Therapeutics AG (CRSP) vs Ecopetrol SA (EC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ecopetrol SA — how do they compare? Crispr Therapeutics AG trades at $54.22 (market cap $5.23B), while Ecopetrol SA trades at $16.91 (market cap $33.69B). The key difference: Ecopetrol SA is far larger — about 6.4× Crispr Therapeutics AG's market cap, and Ecopetrol SA pays a 3.82% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | EC | |
|---|---|---|
Market Cap | $5.23B | $33.69B |
Sector | Health | Energy |
52-Week High | $76.78 | $17.40 |
52-Week Low | $44.34 | $8.56 |
Enterprise Value | $3.65B | $63.86B |
Dividend Yield | — | 3.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
Ecopetrol (EC) trades at $16.93, down 0.7% on the day, with a mixed technical picture showing a bullish moving average signal but neutral oscillators. Fundamentally, the company reported a Q2 2026 EPS beat ($0.858 actual vs. $0.79 expected) but faces declining revenue and net income trends. Recent news includes a cybersecurity incident in July 2026 and the acquisition of a stake in Brava Energia in August 2026.
The outlook is cautious. While valuation ratios appear reasonable (P/E of 11.11, P/S of 0.97), declining profitability and a mixed analyst consensus (27% Buy, 55% Hold) suggest limited near-term upside. Key risks include operational pressures from falling revenue, high debt levels, and the financial impact of the recent cyberattack.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →
